作者
Philippe Moreau,Alfred L. Garfall,Niels W.C.J. van de Donk,Hareth Nahi,Jesús F. San Miguel,Albert Oriol,Ajay K. Nooka,Thomas G. Martin,Laura Rosiñol,Ajai Chari,Lionel Karlin,Lotfi Benboubker,María‐Victoria Mateos,Nizar J. Bahlis,Rakesh Popat,Britta Besemer,Joaquín Martínez‐López,Surbhi Sidana,Michel Attal,Lixia Pei,Danielle Trancucci,Raluca Verona,Suzette Girgis,Shun Xin Wang Lin,Yunsi Olyslager,Mindy Jaffe,Clarissa Uhlar,Tara Stephenson,Rian Van Rampelbergh,Arnob Banerjee,Jeffrey L. Goldberg,Rachel Kobos,Amrita Krishnan,Saad Z. Usmani
摘要
Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.
乐乐乐乐乐乐
Priscilla
VDC
寻道图强
加菲丰丰
贰鸟
shinysparrow
杳鸢
nenoaowu
可口可乐了
sirius
HEIKU
英俊的铭
共享精神
Ava
祥梦伊飞
mmyhn
大卫在分享
Singularity
Ernie
皖公网安备34019202002308
